ArticleBiochemistry and biophysics reports2026
The Farnesoid X receptor-bile acid axis contributes to immune evasion in gastric cancer and its inhibition enhances efficacy of anti-PD-L1 therapy.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer ranks among the most prevalent malignancies globally and remains a major contributor to cancer-related mortality. Its progression is profoundly shaped by the tumor microenvironment (TME), a dynamic milieu comprising extracellular matrix components, soluble mediators, and diverse non-malignant immune populations that collectively influence tumor initiation and evolution. Although immunotherapeutic strategies have recently attracted increasing attention in the management of solid tumors, including gastric carcinoma, the determinants of immune evasion in this context are still not fully delineated. The Farnesoid X receptor (FXR), a key nuclear receptor for bile acids, has recently been implicated in regulating TME composition and immune cell recruitment within gastric tumors. Yet, how bile acid signaling contributes to the bidirectional interactions between malignant and immune cells remains largely undefined. This study aimed to investigate the role of FXR in modulating immune-regulatory networks associated with PD-L1/PD-1 in gastric cancer. RNA-seq analysis of paired gastric mucosa from 39 gastric cancer patients revealed significant molecular differences between intestinal and diffuse tumors. FXR was overexpressed in the intestinal subtype and correlated with poor prognosis. MS/MS analysis demonstrated enrichment of tumor tissues by cholic acid and chenodeoxycholic acid compared to non-neoplastic pairs, supporting the hypothesis of dysregulated bile acid metabolism. In vitro, exposure of gastric cancer cell lines and patient-derived organoids to FXR ligands increased PD-L1 expression through direct binding of FXR-responsive elements in the PD-L1 promoter. Targeting FXR may offer a therapeutic approach to improve the effectiveness of immunotherapies in intestinal gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.